CMB International Global Markets | Equity Research | Company update

Shanghai Jahwa (600315 CH)

Too early to call for a turnaround but ESOP target is likely hit as a low hanging fruit; Down to HOLD

Jahwa's surprising 1Q was mainly driven by non-core gains and a lower tax rate. The quarter's net profit has marked its 4-year high; however, it is still too early to call for an operation turnaround. Jahwa's 1Q sales momentum was lackluster. For instance, Dr. Yu/Herborist/Maxam/gf was down 13%/18%/9%/11% YoY, with the exception of Liushen/Derma Herborist seeing flattish/7% growth. Discounts and mix change has weighed on GPM, and a stubbornly high selling expense ratio is not helpful to OPM which contracted by 0.7pp to 9.2%. Despite this, management remains upbeat and believes its new brand strategy should rejuvenate growth for the remainder of this year. While we do not see sufficient execution track record to substantiate this initiative, we think Jahwa is likely to attain its ESOP target thanks to a soft comp as a low hanging fruit. Considering sub-peers growth and hence a likely capped near-term earnings upside, we downgrade Jahwa to HOLD.

- **2023 outlook.** Different from a restrained marketing budget, management plans to lift up promotional efforts from 2Q onwards with more KOL collaboration. Management is confident to attain its ESOP target for 2023.
- The multi-brand strategy. Herborist pushing up its hero product strategy in return for extending its e-commerce growth momentum that saw a 35% increase in 1Q23; Dr Yu further intensifying its dermatologist brand image with new launch such as facial cream (for oil skin), repair essence, and other SKU for sensitive skins.
- Earnings change. We largely maintain our 2023/24E revenue estimates. Instead, we lower our administration expense ratio by 0.5pp as we believe Jahwa's management will have to maintain a cost-efficient operation to hit its ESOP target as a last resort. Meanwhile, we raise our selling expense ratio by 0.3pp to factor-in more aggressive promotional effort starting from 2Q. Our 2023E estimates are set marginally at the low end of the ESOP B target.
- Valuation. Our revised TP is based on an updated 26.0x (from previously 40.0x) roll-forward end-23E P/E which now represents -1sd below average (from average valuation) since 2019. This was the period when the market began to re-rate the sector in view of the rise of the domestic brands, and subsequently a timely online migration amid the outbreak of COVID-19. Our target multiple is set lower than that of Proya (at long-term average) to reflect the difference in growth outlook and hence our preference.

(YE 31 Dec)	FY21A	FY22A	FY23E	FY24E	FY25E
Revenue (RMB mn)	7,646	7,106	8,051	8,831	9,546
YoY growth (%)	8.7	(7.1)	13.3	9.7	8.1
Net income (RMB mn)	649	472	806	874	986
EPS (RMB)	1.0	0.7	1.2	1.3	1.5
YoY growth (%)	49.6	(27.3)	70.8	8.3	12.9
Consensus EPS (RMB)	n.a	n.a	1.3	1.5	1.7
P/E (x)	n.a	n.a	25.0	23.1	20.5
P/B (x)	n.a	n.a	2.6	2.4	2.2
Div yield (%)	n.a	n.a	1.2	1.3	1.5
ROE (%)	9.3	6.5	10.3	10.4	10.8
Net gearing (%)	net cash				

Source: Company data, Bloomberg, CMBIGM estimates



HOLD (Down)

Target Price	RMB30.9
(Previous TP	RMB39.2)
Up/Downside	+3.9%
Current Price	RMB29.7

China Consumer

Joseph Wong (852) 3900 0838 josephwong@cmbi.com.hk

Stock Data

Mkt Cap (RMB mn)	20,074
Avg 3 mths t/o (RMB mn)	194.5
52w High/Low (RMB)	43.53/ 26.83
Total Issued Shares (mn)	678.9
Source: Wind	

Shareholding Structure

Shanghai Jiahua (Group) Co.	50.8%
Shanghai Jiushi Group Co.	3.9%
SH Chongyang Strategic Inv	2.8%
Source: Wind	

Share Performance

	Absolute	Relative
1-mth	-2.4%	-1.2%
3-mth	-5.7%	-3.6%
6-mth	1.0%	-6.0%
Source: Wind		

12-m Price Performance



Source: Wind

Related Reports

- 1. Proya Cosmetics (603605 CH) 1Q in line; 2023 guidance maintained – 21 Apr 2023
- Proya Cosmetics (603605 CH) 3Q a small beat; but the implied 4Q numbers look unexciting given the current guidance – 18 Oct 2022
- Proya Cosmetics (603605 CH) 2Q in line with full year guidance maintained – 26 Aug 2022
- 4. <u>China Cosmetics The crown jewel</u> of the consumption spectrum: initiate Botanee/ Proya/ Jahwa with Buy – 21 Jun 2022



Figure 1: Earnings revision


		New		Old		Diff (%)			
RMB mn	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E
Revenue	8,051	8,831	9,546	8,154	8,799	NA	-1.3%	0.4%	NA
Gross Profits	4,781	5,320	5,811	4,855	5,345	NA	-1.5%	-0.5%	NA
EBIT	717	907	1,040	674	834	NA	6.4%	8.8%	NA
Net profits	806	874	986	755	884	NA	6.8%	-1.2%	NA
Gross Margins	59.4%	60.2%	60.9%	59.5%	60.7%	NA	-0.2ppt	-0.5ppt	NA
EBIT Margins	8.9%	10.3%	10.9%	8.3%	9.5%	NA	0.6ppt	0.8ppt	NA
Net margins	10.0%	9.9%	10.3%	9.3%	10.0%	NA	0.8ppt	-0.2ppt	NA

Source: Company data, CMBIGM estimates


Figure 2: CMBIGM estimates vs consensus


	(Consensus		Diff (%)					
RMB mn	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E
Revenue	8,051	8,831	9,546	8,248	9,362	10,470	-2.4%	-5.7%	-8.8%
Gross Profits	4,781	5,320	5,811	4,960	5,712	6,480	-3.6%	-6.9%	-10.3%
EBIT	717	907	1,040	825	1,057	1,271	-13.1%	-14.2%	-18.2%
Net profits	806	874	986	756	954	1,135	6.6%	-8.4%	-13.1%
Gross Margins	59.4%	60.2%	60.9%	60.1%	61.0%	61.9%	-0.7ppt	-0.8ppt	-1ppt
EBIT Margins	8.9%	10.3%	10.9%	10.0%	11.3%	12.1%	-1.1ppt	-1ppt	-1.3ppt
Net Margins	10.0%	9.9%	10.3%	9.2%	10.2%	10.8%	0.8ppt	-0.3ppt	-0.5ppt

Source: Company data, CMBIGM estimates









Source: Company data, Bloomberg, CMBIGM estimates



Financial Summary

Income statement						Cash flow summary					
YE 31 Dec (RMB mn)	FY21A	FY22A	FY23E	FY24E	FY25E	YE 31 Dec (RMB mn)	FY21A	FY22A	FY23E	FY24E	FY25E
Revenue	7,646	7,106	8,051	8,831	9,546	Net income	649	472	755	879	988
Major business	7,638	7,099	8,044	8,823	9,539	D&A	209	196	190	197	206
Others	8	7	7	7	7	Change in working capital	100	(75)	(317)	(56)	(134)
						Others	35	72	-	-	-
Gross profit	4,491	4,059	4,781	5,320	5,811	Net cash fr. operating act.	993	665	628	1,019	1,060
Tax and surcharges	(59)	(48)	(55)	(60)	(65)	Capex & investments	(141)	(114)	(253)	(278)	(300)
Selling expenses	(2,947)	(2,652)	(3,140)	(3,444)	(3,723)	Investments	(5,186)	(3,574)	400	400	400
Administrative expenses	(791)	(628)	(692)	(759)	(821)	Others	4,943	3,533	-	-	-
R&D expenses	(163)	(160)	(177)	(194)	(210)	Net cash fr. investing act.	(384)	(155)	147	122	100
EBIT	531	570	717	863	992	_					
						Dividend payment	(197)	(142)	(226)	(264)	(296)
EBITDA	740	766	907	1,060	1,198	Cash from investment	47	17	-	-	-
						Change in borrowing	-	-	-	-	-
Finance costs, net	(13)	11	10	9	7	Others	(79)	(259)	(100)	(100)	(100)
Other income/(expense)	234	(37)	150	150	150	Net cash fr. financing act.	(228)	(384)	(326)	(364)	(396)
Non-operating	12	5	-	-	-						
Pre-tax profit	764	549	878	1,022	1,149	Net change in cash	311	88	448	778	763
						Cash at the beginning of the year	1,287	1,597	1,685	2,133	2,911
Income tax	(115)	(77)	(123)	(143)	(161)	Exchange difference	(71)	(38)	-	-	-
Less: Minority interests	-	-	-	-	-	Cash at the end of the year	1,527	1,647	2,133	2,911	3,674
Net profit	649	472	755	879	988	Less: pledged cash	-	-	-	-	-

Balance sheet						Key ratios					
YE 31 Dec (RMB mn)	FY21A	FY22A	FY23E	FY24E	FY25E	YE 31 Dec	FY21A	FY22A	FY23E	FY24E	FY25E
Non-current assets	5,365	5,715	5,778	5,859	5,953	Sales mix (%)	100.0	100.0	100.0	100.0	100.0
PP&E/Fixed assets	939	863	886	919	959	Major business	99.9	99.9	99.9	99.9	99.9
Net intangibles	761	790	831	879	933	Others	0.1	0.1	0.1	0.1	0.1
Goodwill	1,923	1,938	1,938	1,938	1,938						
Other non-current assets	1,742	2,123	2,123	2,123	2,123	P&L ratios (%)					
						Gross margin	58.7	57.1	59.4	60.2	60.9
Current assets	6,780	6,555	6,748	7,237	7,786	Operating margin	6.9	8.0	8.9	9.8	10.4
Cash	1,597	1,685	2,133	2,911	3,674	Pre-tax margin	10.0	7.7	10.9	11.6	12.0
Account receivable	1,109	1,324	1,323	1,452	1,569	Net margin	8.5	6.6	9.4	10.0	10.4
Prepayments	83	72	72	72	72	Effective tax rate	(15.1)	(14.0)	(14.0)	(14.0)	(14.0)
Inventory	872	929	1,075	1,058	1,126						
Other current assets	3,119	2,544	2,144	1,744	1,344	Balance sheet analysis					
						Current ratio (x)	0.2	0.3	0.3	0.4	0.5
Current liabilities	3,210	3,533	3,362	3,417	3,468	Net receivable days	53	68	60	60	60
Borrowings	-	-	-	-	-	Net payable days	83	110	83	83	83
Accounts payable	718	915	744	798	849	Inventory turnover days	101	111	120	110	110
Other payables	1,790	1,686	1,686	1,686	1,686	Net debt to equity (%)	net cash				
other current liabilities	701	933	933	933	933						
						Returns (%)					
Non-current liabilities	1,972	1,487	1,387	1,287	1,187	ROE	9.3	6.5	9.7	10.5	10.9
Borrowings	925	751	651	551	451	ROA	5.3	3.8	6.0	6.7	7.2
Deferred tax liabilities	123	114	114	114	114	Dividend yield	1.0	0.7	1.2	1.3	1.5
Other non-current liabilities	924	621	621	621	621						
						Per share					
Minority Interest	-	-	-	-	-	EPS (RMB)	1.0	0.7	1.1	1.3	1.5
Total net assets	6,963	7,249	7,778	8,393	9,084	DPS (RMB)	0.3	0.2	0.3	0.4	0.4
Shareholders' equity	6,963	7,249	7,778	8,393	9,084	BVPS (RMB)	10.3	10.7	11.5	12.4	13.4

Source: Company data, CMBIGM estimates



Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings BUY HOLD SELL NOT RATED	: Stock with potential return of over 15% over next 12 months : Stock with potential return of +15% to -10% over next 12 months : Stock with potential loss of over 10% over next 12 months : Stock is not rated by CMBIGM
OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM. Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time)("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBIGMG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBIGMG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBIGMG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBIGMG at +65 6350 4400 for matters arising from, or in connection with the report.